Structural Insights Accelerate the Discovery of Opioid Alternatives
- PMID: 33756098
- DOI: 10.1146/annurev-biochem-061620-044044
Structural Insights Accelerate the Discovery of Opioid Alternatives
Abstract
Opioids such as morphine and oxycodone are analgesics frequently prescribed for the treatment of moderate or severe pain. Unfortunately, these medications are associated with exceptionally high abuse potentials and often cause fatal side effects, mainly through the μ-opioid receptor (MOR). Efforts to discover novel, safer, and more efficacious analgesics targeting MOR have encountered challenges. In this review, we summarize alternative strategies and targets that could be used to develop safer nonopioid analgesics. A molecular understanding of G protein-coupled receptor activation and signaling has illuminated not only the complexities of receptor pharmacology but also the potential for pathway-selective agonists and allosteric modulators as safer medications. The availability of structures of pain-related receptors, in combination with high-throughput computational tools, has accelerated the discovery of multitarget ligands with promising pharmacological profiles. Emerging clinical evidence also supports the notion that drugs targeting peripheral opioid receptors have potential as improved analgesic agents.
Keywords: GPCR; analgesic; nonopioid; opioid receptor; opioids; side effects.
Similar articles
-
Multitarget ligands that comprise opioid/nonopioid pharmacophores for pain management: Current state of the science.Pharmacol Res. 2024 Nov;209:107408. doi: 10.1016/j.phrs.2024.107408. Epub 2024 Sep 21. Pharmacol Res. 2024. PMID: 39307212 Review.
-
Mu-Opioid receptor biased ligands: A safer and painless discovery of analgesics?Drug Discov Today. 2017 Nov;22(11):1719-1729. doi: 10.1016/j.drudis.2017.07.002. Epub 2017 Jul 22. Drug Discov Today. 2017. PMID: 28743488 Free PMC article. Review.
-
Replacement of current opioid drugs focusing on MOR-related strategies.Pharmacol Ther. 2020 Jun;210:107519. doi: 10.1016/j.pharmthera.2020.107519. Epub 2020 Mar 9. Pharmacol Ther. 2020. PMID: 32165137 Review.
-
Peptide-derived ligands for the discovery of safer opioid analgesics.Drug Discov Today. 2024 May;29(5):103950. doi: 10.1016/j.drudis.2024.103950. Epub 2024 Mar 20. Drug Discov Today. 2024. PMID: 38514040 Free PMC article. Review.
-
Emerging Insights into Mu Opioid Pharmacology.Handb Exp Pharmacol. 2020;258:89-125. doi: 10.1007/164_2019_270. Handb Exp Pharmacol. 2020. PMID: 31598835 Review.
Cited by
-
GPCR-G protein selectivity revealed by structural pharmacology.FEBS J. 2024 Jul;291(13):2784-2791. doi: 10.1111/febs.17049. Epub 2024 Jan 8. FEBS J. 2024. PMID: 38151714 Free PMC article. Review.
-
CYX-5, a G-protein biassed MOP receptor agonist, DOP receptor antagonist and KOP receptor agonist, evokes constipation but not respiratory depression relative to morphine in rats.Pharmacol Rep. 2023 Jun;75(3):634-646. doi: 10.1007/s43440-023-00446-8. Epub 2023 Jan 13. Pharmacol Rep. 2023. PMID: 36637684 Free PMC article.
-
Exploring Novel Antidepressants Targeting G Protein-Coupled Receptors and Key Membrane Receptors Based on Molecular Structures.Molecules. 2024 Feb 22;29(5):964. doi: 10.3390/molecules29050964. Molecules. 2024. PMID: 38474476 Free PMC article. Review.
-
Spotlight on Nociceptin/Orphanin FQ Receptor in the Treatment of Pain.Molecules. 2022 Jan 18;27(3):595. doi: 10.3390/molecules27030595. Molecules. 2022. PMID: 35163856 Free PMC article. Review.
-
In Vitro and In Vivo Pharmacological Profiles of LENART01, a Dermorphin-Ranatensin Hybrid Peptide.Int J Mol Sci. 2024 Apr 3;25(7):4007. doi: 10.3390/ijms25074007. Int J Mol Sci. 2024. PMID: 38612817 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials